Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05824689 · ClinicalTrials.gov registry record
Fluoroquinolone Resistance Prevalence Study
A clinical trial, sponsored by Hackensack Meridian Health.
- Terminated
- Registry status
- 124
- Enrollment target
NCT05824689: Clinical Trial study, sponsored by Hackensack Meridian Health.
NCT05824689 is a clinical trial that was terminated before completion, run by Hackensack Meridian Health. The registered enrollment target is 124 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05824689 was terminated before completion, sponsored by Hackensack Meridian Health.
- TERMINATED
- Registry status
- 124 participants
- Enrollment target
Study Summary
This is an exploratory study to determine the prevalence of fluoroquinolone resistance in patients receiving dose-intense melphalan with autologous peripheral blood stem cell (PBSC) transplantation in the treatment of multiple myeloma (MM). These data may be used in subsequent studies exploring the use of prophylaxis in this patient population.
Primary Outcome
Prevalence of FRE in patients undergoing autologous PBSC transplantation with dose-intense melphalan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2022-07-08 |
| Est. Completion | 2025-01-15 |
Why NCT05824689 stopped before completion
NCT05824689 is an observational study that tracks outcomes without assigning an intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05824689 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05824689 about?
NCT05824689 is a clinical study titled "Fluoroquinolone Resistance Prevalence Study". This is an exploratory study to determine the prevalence of fluoroquinolone resistance in patients receiving dose-intense melphalan with autologous peripheral blood stem cell (PBSC) transplantation in the treatment of multiple myeloma (MM). These data may be used in subsequent studies exploring the...
What is the current status of trial NCT05824689?
This trial is currently terminated. The enrollment target is 124 participants. The study started on 2022-07-08. Estimated completion is 2025-01-15.
Who is sponsoring clinical trial NCT05824689?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI